Targeting NLRP3: DFV890 and Beyond
The article reviews the NLRP3 inflammasome inhibitor DFV890, highlighting its Phase 2 data in acute coronary syndrome and its mechanism of selectively blocking NLRP3 activation. It also examines emerging NLRP3‑targeted programs, including covalent inhibitors and PROTAC degraders, and discusses the broader shift toward small‑molecule inflammasome therapeutics. The piece underscores the growing clinical validation of NLRP3 as a druggable target and the competitive landscape shaping future pipelines.
Mirdametinib (PD0325901)
Springworks Therapeutics and Pfizer announced FDA approval of mirdametinib (PD0325901), an oral, brain‑penetrant MEK1/2 inhibitor for treating neurofibromatosis type 1‑associated plexiform neurofibromas (NF1‑PN) in both adults and children. The drug was optimized from an earlier in‑vitro tool compound to improve potency...
Fenebrutinib (GDC-0853)
Fenebrutinib (GDC‑0853) is an oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that entered Phase 3 trials for multiple sclerosis in a November 2025 press release. The drug was discovered through ATP‑site‑directed compound library screening and subsequently optimized by Roche and Genentech. Its...
Patenting Strategies for Small Molecule Drugs
The article reviews patenting strategies for small‑molecule drugs, emphasizing the need for early and comprehensive protection. It outlines the typical patent lifecycle—from provisional filings through PCT applications to national‑phase prosecution—and the legal standards of utility, novelty, and non‑obviousness. Real‑world examples...
A Compendium of Pharmaceutical Salts to Help Flavor Your Drug Formulation
The article presents a comprehensive list of pharmaceutical salts that can be leveraged to enhance the taste, solubility, and overall patient acceptability of oral drug formulations. It outlines the physicochemical properties, regulatory status, and typical applications of both traditional inorganic...